Exavir Therapeutics Inc.
Capital Timeline
Capital this company has received, each line traceable to a primary record. Amounts are obligations, not contract ceilings.
A blank stage means the data is not ingested yet, not that the money stopped there.
- National Institutes of Health$998K1
Why It Matters
Not enough signal yet to assess this company's relevance to Japanese firms.
Events
Events used as evidence for Stage / LCI. Facts and interpretation are recorded separately.
EXAVIR THERAPEUTICS INC. — Grant R44AI195119
DEVELOPMENT OF AN ULTRA-LONG-ACTING, SELF-ADMINISTERED, DOLUTEGRAVIR-BASED TREATMENT REGIMEN FOR HIV-1 AND HIV-HBV CO-INFECTION - PROJECT SUMMARY DESPITE PROGRESS IN LONG-ACTING (LA) ANTIRETROVIRALS (ARVS) FOR HIV TREATMENT IN RECENT YEARS, THERE REMAINS A SIGNIFICANT UNMET NEED FOR ADDITIONAL AND BETTER LA ARVS ANTIRETROVIRALS FOR PATIENTS, INCLUDING KEY PATIENT POPULATIONS AND MARKET SEGMENTS THAT WILL REMAIN UNDERSERVED. FIRST, THE ONLY AVAILABLE LA COMPLETE TREATMENT REGIMEN AND IS COMPRISED OF SUBOPTIMAL ARVS WITH LESSER POTENCY VS. GUIDELINE-PREFERRED ORAL-ONLY AGENTS. SECOND, CABENUVA REQUIRES INTRAMUSCULAR (IM) DOSING ADMINISTERED BY HEALTHCARE PROVIDERS EVERY ONE OR TWO MONTHS, MORE FREQUENTLY THAN THE TYPICAL CLINIC VISIT SCHEDULE FOR PLWH ON A STABLE TREATMENT REGIMEN. THIRD, HIV-1 IS MORE SUSCEPTIBLE TO DEVELOPING PRIMARY DRUG RESISTANCE TO CAB AND LEN COMPARED TO GUIDELINE- PREFERRED ORAL-ONLY AGENTS. FOURTH, NONE OF THE APPROVED OR PUBLICLY ANNOUNCED INVESTIGATIONAL LA OR
Timeline
No timeline articles for this company yet.